5499-31-0

Upstream product

• 16182-04-0 Ethoxycarbonyl isothiocyanate 
• 71-43-2 benzene 

Downstream Products

• 82256-16-4 2-Phenyl-6,7-dihydro-4H-thiazolo<3,2-a>-1,3,5-triazin-4-one 
• 1357927-39-9 ethyl (1-ethyl-1H-indol-5-ylamino)(phenyl)methylenecarbamate 
• 1357927-44-6 7-ethyl-3-phenyl-2,7-dihydro-1H-pyrrolo[3,2-f]quinazolin-1-one 
• 1357927-46-8 7-cyclopropylmethyl-3-phenyl-2,7-dihydro-1H-pyrrolo[3,2-f]quinazolin-1-one 
• 1357927-41-3 ethyl (1-(cyclopropylmethyl)-1H-indol-5-ylamino)(phenyl)methylenecarbamate 
• 1357927-45-7 7-propyl-3-phenyl-2,7-dihydro-1H-pyrrolo[3,2-f]quinazolin-1-one 
• 1357927-40-2 ethyl (1-propyl-1H-indol-5-ylamino)(phenyl)methylenecarbamate 
• 1357927-38-8 C₁₈H₁₇N₃O₂ 
• 1357927-43-5 3-phenyl-2,7-dihydro-1H-pyrrolo[3,2-f]quinazolin-1-one 
• 205058-48-6 9H-Fluoren-9-ylmethyl-4-(5-oxo-3-phenyl-4,5-dihydro-1H-1,2,4-triazol-1-yl)piperidine-1-carboxylate 
• 639520-39-1 ({1-[1(S)-(benzoxazol-2-ylcarbontl)-propylcarbamoyl]-2(R)-phenylmethanesulfonylethylamino}phenylmethylene)carbamic acid ethyl ester 
• 55103-08-7 6,7-Dihydro-2-phenyl-4H-thiazolo<3,2-a>-1,3,5-triazine-4-thione 
• 1022-45-3 2-phenyl-4(3H)-quinazolinone 
• 220327-56-0 10-Chloro-3-phenyl-5,6-dihydro-1H-pyrido[3,2,1-ij]quinazolin-7-one 

Relevant academic research and scientific papers

Synthesis and evaluation of platelet aggregation inhibitory activity of some 3-phenyl-pyrroloquinazolinones

A series of 3-phenyl-2,7-dihydro-1H-pyrrolo[3,2-f]quinazolin-1-one derivatives (3-PPyQZ) was synthesized starting from 5-amino-indoles, via condensation with N-ethoxycarbonylthiobenzamides followed by thermal cyclization. On the basis of their structural analogy with reported anti-thrombin pyrroloquinazolines, the derivatives were first tested for their capacity to inhibit platelet aggregation. Some of them had in vitro inhibitory effects on collagen and thrombin-induced aggregation in the micromolar range, and much higher inhibition than that shown by some phenyl-pyrroloquinolinones. Experiments to determine the mechanism of action of the most potent inhibitor (compound 18) indicated that it acts in at least two sites: one preceding the agonist-induced increase of cytosolic [Ca2+], and one following this step of the platelet activation cascade. The compound also inhibited thrombin-evoked protein-Tyr-phosphorylation. Although it is premature to draw definitive conclusions, the present results indicate that 3-PPyQZ structure, with the quite potent inhibitor of platelet aggregation compound 18, might constitute a starting point for the synthesis of potential anti-thrombosis agents.

AMIDE-SUBSTITUTED ARYL PIPERIDINES

Amide-substituted aryl piperidines derivatives of the following Formulas are provided:(Formulas), in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache, such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.

BIARYL KETONE-SUBSTITUTED PIPERIDINES

Biaryl ketone-substituted piperidines of the following Formulas are provided:, and in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.